The Estimated Direct Medical Cost of Selected Sexually Transmitted Infections in the United States, 2008
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Millions of cases of sexually transmitted infections (STIs) occur in the United States each year, resulting in substantial medical costs to the nation. Previous estimates of the total direct cost of STIs are quite dated. We present updated direct medical cost estimates of STIs in the United States. METHODS: We assembled recent (i.e., 2002-2011) cost estimates to determine the lifetime cost per case of 8 major STIs (chlamydia, gonorrhea, hepatitis B virus, human immunodeficiency virus (HIV), human papillomavirus, genital herpes simplex virus type 2, trichomoniasis and syphilis). The total direct cost for each STI was computed as the product of the number of new or newly diagnosed cases in 2008 and the estimated discounted lifetime cost per case. All costs were adjusted to 2010 US dollars. RESULTS: Results indicated that the total lifetime direct medical cost of the 19.7 million cases of STIs that occurred among persons of all ages in 2008 in the United States was $15.6 (range, $11.0-$20.6) billion. Total costs were as follows: chlamydia ($516.7 [$258.3-$775.0] million), gonorrhea ($162.1 [$81.1-$243.2] million), hepatitis B virus ($50.7 [$41.3-$55.6] million), HIV ($12.6 [$9.5-$15.7] billion), human papillomavirus ($1.7 [$0.8-$2.9] billion), herpes simplex virus type 2 ($540.7 [$270.3-$811.0] million), syphilis ($39.3 [$19.6-$58.9] million), and trichomoniasis ($24.0 [$12.0-$36.0] million). Costs associated with HIV infection accounted for more than 81% of the total cost. Among the nonviral STIs, chlamydia was the most costly infection. CONCLUSIONS: Sexually transmitted infections continue to impose a substantial cost burden on the payers of medical care in the United States. The burden of STIs would be even greater in the absence of STI prevention and control efforts.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For females, the cost per STI case ranges from $247 for Human Papilloma Virus (HPV) to $804 for Herpes-Simples Virus (HSV2).”
From Monetary conversion factors for economic evaluations of substance use disorders (2017) · cites this paper as Owusu-Edusei et al., 2013
In the citing paper
“The average cost per case of syphilis is $918 (either gender).”
From Monetary conversion factors for economic evaluations of substance use disorders (2017) · cites this paper as Owusu-Edusei et al., 2013
In the citing paper
“For males, the cost per case ranges from $39 for Chlamydia to $985 for HSV2.”
From Monetary conversion factors for economic evaluations of substance use disorders (2017) · cites this paper as Owusu-Edusei et al., 2013
Citations
Cites
Gardner, E. M., McLees, M. P., Steiner, J. F., del Rio, C., & Burman, W. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq243 · Cited by 1,893 · cited 1×
“However, this estimate is applicable when considering the best-case scenario of HIV care in the United States, implying that applying their estimate could overestimate the total direct cost of HIV, because not all patients with HIV receive care and not all those who receive care get the best care available.(25,26) Hut…”
BackgroundSexually Transmitted Infections Among US Women and Men: Prevalence and Incidence Estimates, 2008
Satterwhite, C. L., Torrone, E., Meites, E., Dunne, E. F., Mahajan, R., Ocfemia, M. C. B., Su, J., Xu, F., & Weinstock, H. (2013) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e318286bb53 · Cited by 1,260
Self-citationSexually Transmitted Diseases Among American Youth: Incidence and Prevalence Estimates, 2000
Weinstock, H., Berman, S., & Cates, W. (2004) · Perspectives on Sexual and Reproductive Health · doi:10.1363/3600604 · Cited by 1,258
Sexually Transmitted Diseases Among American Youth: Incidence and Prevalence Estimates, 2000
Weinstock, H., Berman, S., & Cates, W. (2004) · Perspectives on Sexual and Reproductive Health · doi:10.1111/j.1931-2393.2004.tb00002.x · Cited by 1,153
Estimated HIV Incidence in the United States, 2006–2009
Prejean, J., Song, R., Hernandez, A., Ziebell, R., Green, T., Walker, F., Lin, L. S., An, Q., Mermin, J., Lansky, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017502 · Cited by 1,071 · cited 1×
“For instance, in the past few years, the reported annual incidence of chlamydia, syphilis, and genital warts has increased,(6) although the annual incidence of gonorrhea and HIV infection has been relatively stable.(6,7) In addition, given the rapid changes in health care technology and service delivery, the lifetime…”
BackgroundRisk of Sequelae after Chlamydia trachomatis Genital Infection in Women
Haggerty, C. L., Gottlieb, S. L., Taylor, B. D., Low, N., Xu, F., & Ness, R. B. (2010) · The Journal of Infectious Diseases · doi:10.1086/652395 · Cited by 657 · cited 1×
“5% of treated asymptomatic cases in women, with no PID assumed to develop in treated women with symptomatic chlamydia.(15) We assumed epididymitis developed in 1.”
BackgroundThe Estimated Direct Medical Cost of Sexually Transmitted Diseases Among American Youth, 2000
Chesson, H. W., Blandford, J. M., Gift, T. L., Tao, G., & Irwin, K. L. (2004) · Perspectives on Sexual and Reproductive Health · doi:10.1363/3601104 · Cited by 444 · cited 8×
“Screening costs for asymptomatic persons were not included; in our previous estimate, these costs were included as part of the overall burden of chlamydia for persons infected with chlamydia.(1) We used previously published estimates of diagnosis and treatment costs for patients diagnosed in private physician/ health…”
BackgroundMethodResultInfluentialSelf-citationDevelopment and Duration of Human Papillomavirus Lesions, after Initial Infection
Winer, R. L., Kiviat, N. B., Hughes, J. P., Adam, D. E., Lee, S., Kuypers, J. M., & Koutsky, L. A. (2005) · The Journal of Infectious Diseases · doi:10.1086/427557 · Cited by 417
The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States
Schackman, B. R., Gebo, K. A., Walensky, R. P., Losina, E., Muccio, T., Sax, P. E., Weinstein, M. C., Seage, G. R., Moore, R. D., & Freedberg, K. A. (2006) · Medical Care · doi:10.1097/01.mlr.0000228021.89490.2a · Cited by 410 · cited 5×
“We reviewed 2 recent studies that estimated the direct lifetime cost of HIV infection in the United States (Schackman et al.(23) and Hutchinson et al.”
BackgroundMethodInfluentialHs, M. (1995) · JAMA · doi:10.1001/jama.274.15.1201 · Cited by 323 · cited 1×
“For example, the potential costs of liver transplantation were included in the 3 source studies cited earlier, whereas liver transplantation costs were not reflected in our original estimate.(1,22)”
BackgroundUniversal Voluntary Testing and Treatment for Prevention of HIV Transmission
Dieffenbach, C. W. (2009) · JAMA · doi:10.1001/jama.2009.828 · Cited by 269 · cited 1×
“However, this estimate is applicable when considering the best-case scenario of HIV care in the United States, implying that applying their estimate could overestimate the total direct cost of HIV, because not all patients with HIV receive care and not all those who receive care get the best care available.(25,26) Hut…”
BackgroundDiagnoses and outcomes in cervical cancer screening: A population-based study
Insinga, R. P., Glass, A. G., & Rush, B. B. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.01.043 · Cited by 259
Holtgrave, D. R., & Pinkerton, S. D. (1997) · Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology · doi:10.1097/00042560-199709010-00009 · Cited by 229
Chesson, H. W., Ekwueme, D. U., Saraiya, M., Watson, M., Lowy, D. R., & Markowitz, L. E. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.056 · Cited by 205 · cited 2×
“The ranges for the cost per case of HPV reflect the same relative range for the overall incidence cost of HPV-associated diseases.(28) The estimated cost per case in women is notably lower than our previous estimate for 2 main reasons.”
BackgroundMethodSelf-citationHutchinson, A. B., Farnham, P. G., Dean, H. D., Ekwueme, D. U., del Río, C., Kamimoto, L., & Kellerman, S. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000243090.32866.4e · Cited by 135 · cited 6×
“Hutchinson et al.(24) used data from the HIV Cost and Services Utilization Study and accounted for the ‘‘proportion of persons who had ever used antiretroviral therapy (ART), reported by race/ethnicity (white, 78%; black, 59%; Hispanic, 73%; and other, 77%).”
BackgroundMethodInfluentialA Refined Estimate of the Average Lifetime Cost of Pelvic Inflammatory Disease
YEH, J. M., HOOK, E. W., & GOLDIE, S. J. (2003) · Sexually Transmitted Diseases · doi:10.1097/00007435-200305000-00001 · Cited by 121 · cited 1×
“Costs of sequelae, principally pelvic inflammatory disease (PID; $3202) and epididymitis in men ($313), were included using previously published estimates.(12,13) We assumed that 20% of chlamydial infections in both men and women would be symptomatic and that 89% of these cases would be treated.”
MethodMagid, D. J., Douglas, J. M., & Schwartz, J. S. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-4-199602150-00002 · Cited by 111 · cited 1×
“5% of untreated men.(16) On the basis of these assumptions and costs, we estimated that the lifetime costs per case of chlamydial infection were $30 (range, $15Y$45) for men and $364 (range, $182Y$546) for women in 2010 US dollars.”
BackgroundCost-effectiveness of hepatitis B vaccination of prison inmates
Pisu, M., Meltzer, M. I., & Lyerla, R. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00457-7 · Cited by 60
Incidence and Costs of Cervical Intraepithelial Neoplasia in a US Commercially Insured Population
Henk, H. J., Insinga, R. P., Singhal, P. K., & Darkow, T. (2009) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0b013e3181ac05e9 · Cited by 56
FISMAN, D. N., LIPSITCH, M., HOOK, E. W., & GOLDIE, S. J. (2002) · Sexually Transmitted Diseases · doi:10.1097/00007435-200210000-00008 · Cited by 55 · cited 1×
“These previously published estimates were generated from a published model of the incidence and cost of HSV-2 in the United States(30) and accounted for asymptomatic cases, which incur no costs, a general decline in the rate of relapse over time for those who are symptomatic, and the possibility of uptake of suppressi…”
MethodEconomic Evaluation of Delivering Hepatitis B Vaccine to Injection Drug Users
Hu, Y., Grau, L. E., Scott, G., Seal, K. H., Marshall, P. A., Singer, M. C., & Heimer, R. (2008) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2008.03.028 · Cited by 45
The Cost Effectiveness of Hepatitis Immunization for US College Students
Jacobs, R. J., Saab, S., & Meyerhoff, A. S. (2003) · Journal of American College Health · doi:10.1080/07448480309596355 · Cited by 40
BEGLEY, C. E., McGILL, L., & SMITH, P. B. (1989) · Sexually Transmitted Diseases · doi:10.1097/00007435-198904000-00004 · Cited by 39 · cited 1×
“We used previously published estimates of diagnosis and treatment costs for patients diagnosed in private physician/ health maintenance organization (HMO) health care settings (34%)(10) and other settings including STI, family planning, and other health department clinics and hospitals (66%).(11) The proportion of cas…”
MethodChesson, H. W., Forhan, S. E., Gottlieb, S. L., & Markowitz, L. E. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.06.045 · Cited by 38
Self-citationChesson, H. W., Gift, T. L., Owusu-Edusei, K., Tao, G., Johnson, A. P., & Kent, C. K. (2011) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e318223be77 · Cited by 38 · cited 14×
“Quantifying the direct medical cost of STIs in the United States can help to assess the economic impact of STIs on the population and on those who pay for their medical care.(1,2) To date, there have been 3 major studies of the overall burden of STIs in the United States.”
BackgroundInfluentialSelf-citationGift, T. L., Malotte, C. K., Ledsky, R., Hogben, M., Middlestadt, S. E., VanDevanter, N., & Lawrence, J. S. S. (2005) · Sexually Transmitted Diseases · doi:10.1097/01.olq.0000175414.80023.59 · Cited by 30 · cited 1×
“We assumed that 50% of infections in men and 25% of infections in women would be symptomatic and that 89% of symptomatic cases would be treated.(8,14,18) We assumed that 40% of asymptomatic cases in women would be treated and that 9% of asymptomatic cases in men would be treated.”
BackgroundSelf-citationOwusu‐Edusei, K., Tejani, M. N., Gift, T. L., Kent, C. K., & Tao, G. (2009) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e318199d5fe · Cited by 22
Self-citationThe Direct Medical Cost of Epididymitis and Orchitis: Evidence From a Study of Insurance Claims
Gift, T. L., & Owens, C. J. (2006) · Sexually Transmitted Diseases · doi:10.1097/01.olq.0000235149.41948.fa · Cited by 21 · cited 1×
“Costs of sequelae, principally pelvic inflammatory disease (PID; $3202) and epididymitis in men ($313), were included using previously published estimates.(12,13) We assumed that 20% of chlamydial infections in both men and women would be symptomatic and that 89% of these cases would be treated.”
MethodSelf-citationFoglia, G., Rhodes, P., Goldberg, M., & Louis, M. E. S. (1999) · Sexually Transmitted Diseases · doi:10.1097/00007435-199909000-00001 · Cited by 18 · cited 2×
“We assumed that 20% of chlamydial infections in both men and women would be symptomatic and that 89% of these cases would be treated.(8,14) Of asymptomatic cases, we assumed that 40% (women 15Y24 years), 15% (women 25Y39 years), 9% (men 15Y24 years), and 5% (men 25Y39 years) were treated; these differences reflect dif…”
BackgroundOwusu‐Edusei, K., Doshi, S. R., Apt, B. S., & Gift, T. L. (2010) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e3181d73e4c · Cited by 18
Self-citationOwusu‐Edusei, K., Gift, T. L., & Chesson, H. W. (2010) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e3181c5e643 · Cited by 15
Self-citationOwusu‐Edusei, K., Hoover, K. W., & Tao, G. (2010) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e3181f4207f · Cited by 15
Self-citation
Cited by
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Papp, J. R., Schachter, J., Gaydos, C. A., & Pol, B. J. V. D. (2014) · PubMed · Cited by 823
Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines
Workowski, K. A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ771 · Cited by 588
Lifetime Economic Burden of Intimate Partner Violence Among U.S. Adults
Peterson, C., Kearns, M. C., McIntosh, W. L., Estefan, L. F., Nicolaidis, C., McCollister, K. E., Gordon, A., & Florence, C. (2018) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2018.04.049 · Cited by 471
Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health
Petrova, M. I., Lievens, E., Malik, S., Imholz, N., & Lebeer, S. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00081 · Cited by 523
Metadata
- Authors
- Owusu-Edusei, K., Chesson, H. W., Gift, T. L., Tao, G., Mahajan, R., Ocfemia, M. C. B., & Kent, C. K.
- Corresponding author
- Chesson, Harrell W.
- Gift, Thomas L.
- Tao, Guoyu
- Kent, Charlotte K.
- Venue
- Sexually Transmitted Diseases
- Published
- 2013-03
- Volume
- 40
- Issue
- 3
- Pages
- 197-201
- ISSN
- 0148-5717 (ISSN-L)
- OpenAlex
- W2064915358
- Cited by
- 452
- References
- 32
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 9 · 2023: 20 · 2022: 21 · 2021: 37 · 2020: 39 · 2019: 39 · 2018: 45 · 2017: 75 · 2016: 41 · 2015: 46 · 2014: 53 · 2013: 17
- FWCI
- 47.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Sexually Transmitted Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- sexually transmitted infections, direct medical costs, HIV, chlamydia, gonorrhea, hepatitis B virus, human papillomavirus, herpes simplex virus type 2, syphilis, trichomoniasis, cost burden
- MeSH terms
- Chlamydia Infections, Condylomata Acuminata, Female, Gonorrhea, Hepatitis B, Herpes Genitalis, Humans, Male, Sexually Transmitted Diseases, Syphilis, Trichomonas Infections, United States, HIV Infections, Health Care Costs, Cost of Illness, Models, Economic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.